Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 2093-2101, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knapp, M. L.
Right arrow Articles by Riches, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knapp, M. L.
Right arrow Articles by Riches, P. G.

Clinical Chemistry, Vol 37, 2093-2101, Copyright © 1991 by American Association for Clinical Chemistry

Alterations of serum lipids in breast cancer: effects of disease activity, treatment, and hormonal factors

ML Knapp, S al-Sheibani and PG Riches
Department of Chemical Pathology, St. Peter's Hospital, Chertsey, Surrey, U.K.

Fasting venous blood collected from 83 patients with breast cancer was analyzed for triglycerides; total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol; tumor necrosis factor (TNF alpha); glucose; creatinine; insulin; glucagon; growth hormone; cortisol; and thyrotropin. Patients with stage IV disease had significantly higher (P less than 0.05) triglyceride concentrations and significantly lower (P less than 0.05) concentrations of total and HDL cholesterol than did patients with less advanced disease or age-matched controls. Furthermore, LDL cholesterol concentrations in patients with boney metastases were significantly lower (P less than 0.05) than concentrations in patients with liver or liver plus boney metastases or in controls. These results could not be attributed to smoking habits, alcohol consumption, or treatment. We observed no correlations between serum concentrations of lipid and concentrations of TNF alpha, insulin, glucose, creatinine, cortisol, growth hormone, or thyrotropin. However, there was a significant (P less than 0.05) negative correlation between total cholesterol and glucagon and between LDL cholesterol and glucagon for patients with stage II, III, and IV disease, suggesting that glucagon may reduce LDL cholesterol concentrations by an as-yet- unidentified mechanism.


The following articles in journals at HighWire Press have cited this article:


Home page
 Arch Intern MedHome page
A. H. Eliassen, G. A. Colditz, B. Rosner, W. C. Willett, and S. E. Hankinson
Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer
Arch Intern Med, October 24, 2005; 165(19): 2264 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Nakamura, N. Shibata, T. Nishimoto-Shibata, D. Feng, M. Ikemoto, K. Motojima, N. Iso-o, K. Tsukamoto, M. Tsujimoto, and H. Arai
Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1
PNAS, September 20, 2005; 102(38): 13404 - 13409.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.